Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02316106 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

A Phase 2 study of Multiple Myeloma, sponsored by Janssen Research & Development.

Completed
Registry status
Phase 2
Development phase
123
Enrollment target
20
Study locations

NCT02316106 is a Phase 2 study of Multiple Myeloma that has completed, run by Janssen Research & Development. The registered enrollment target is 123 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02316106, a Phase 2 study of Multiple Myeloma, has completed, sponsored by Janssen Research & Development.

COMPLETED
Registry status
Phase 2
Development phase
123 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate three daratumumab dose schedules in participants with Smoldering Multiple Myeloma.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG daratumumab

Study Locations (20)

Other

  • - Box Hill
  • - Concord
  • - Melbourne
  • - Woodville South

Florida

  • - Jacksonville
  • - West Palm Beach

Ohio

  • - Cincinnati
  • - Columbus

Arkansas

  • - Little Rock

Georgia

  • - Atlanta

Massachusetts

  • - Boston

Michigan

  • - Ann Arbor

Missouri

  • - St Louis

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2015-05-20
Est. Completion 2024-06-03
Phase Phase 2

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02316106

The ClinicalTrials.gov registry entry for NCT02316106 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (77% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which daratumumab is the first listed.

NCT02316106 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, Florida, Ohio.

Frequently Asked Questions

What is clinical trial NCT02316106 about?

NCT02316106 is a clinical study titled "A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma". The purpose of this study is to evaluate three daratumumab dose schedules in participants with Smoldering Multiple Myeloma.

What is the current status of trial NCT02316106?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2015-05-20. Estimated completion is 2024-06-03.

What conditions does trial NCT02316106 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT02316106?

The interventions under investigation include: daratumumab (DRUG).

Who is sponsoring clinical trial NCT02316106?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02316106 being conducted?

This trial has 20 study locations across Arkansas, Florida, Georgia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.